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MNTIn an effort to identify potent and isoform selective inhibitors of PI3Kd, GNE-293 (34) was identiﬁed.
Inhibitor 2 was found to induce micronuclei formation in both the MNT and HCA in vitro assays. Com-
pounds testing negative for genotoxicity were successfully identiﬁed through modiﬁcations of the
2-benzimidazole substituent and the methylene moiety to disrupt planarity. A variety of heteroatom
linkers were explored to examine their effect on potency and isoform selectivity by restricting torsional
angles to favor ligand interactions with PI3Kd’s Trp760. These modiﬁcations also resulted in an improved
in vivo pharmacokinetic proﬁle.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.Phosphoinosotide-3-kinase delta (PI3Kd) is a heterodimeric li-
pid kinase that is highly expressed in lymphocytes and mast cells.1
Recruitment of this kinase to the cellular membrane by activated
extracellular receptors results in the PI3Kd-mediated production
of phosphatidylinositol 3,4,5-trisphosphate PI(3,4,5)P3.2 Increased
cellular concentrations of PI(3,4,5)P3 activate Akt and other regula-
tory kinases, and ultimately cause lymphocyte proliferation, mast
cell degranulation, and other processes associated with inﬂamma-
tory immune response. Mast cell degranulation in response to
IgE-activation is reduced in PI3Kd kinase-dead knock-in mice.3
Similarly, the selective PI3Kd inhibitor 2-((6-amino-9H-purin-9-
yl)methyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one (IC87114, 1)
inhibits mast cell degranulation and can reduce allergic responseto allergen challenge in murine asthma models (Fig. 1). 4 More re-
cently, 1 has been shown to reduce inﬂammation in a mouse auto-
antibody-induced arthritis model.5 These results support the
further investigation of PI3Kd inhibitors for treatment of asthma,
rheumatoid arthritis, and other inﬂammatory disorders.6–8
Most inhibitors of PI3Kd currently in clinical trials also inhibit
the related lipid kinases PI3Ka, PI3Kb, and PI3Kc. Recently how-
ever, several pharmaceutical companies have described selective
inhibitors of PI3Kd that resemble IC87114 (1).9 This class of inhib-
itor generally binds to PI3Kd by occupying a unique hydrophobic
cavity between Trp760 and Met750 in the PI3Kd ATP binding
pocket.10,11 We have recently described structurally distinct selec-
tive PI3Kd inhibitor 2. (Fig. 1) 12,13 This compound is structurally
related to the clinical pan-PI3K inhibitor 3 (GDC-0941).14 Benz-
imidazole 2 selectively inhibited PI3Kd relative to closely related li-
pid kinases and had attractive pharmaceutical properties.
Avoiding the potential for carcinogenicity during the discovery
lead optimization is critical for non-life-threatening indications.
The International Conference on Harmonisation (ICH) has pro-
posed a standard genetic toxicology battery of tests (both in vitro
and in vivo) for the prediction of potential human risk.15 In order
to assess the carcinogenic potential of drugs on humans, extensive
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Figure 1. Isoform selective and non-selective PI3Kd inhibitors.
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prior to application for IND and marketing approval. Prior to mak-
ing this large commitment of resources, in vitro assays for genotox-
ins are generally accepted as adequate to de-risk carcinogenicity
during lead optimization. These assays can be broadly divided into
two subclasses: those that detect direct genetic mutation (i.e., the
Ames test) and those that detect damage to chromosomes, for
example human chromosome aberration (HCA) and micronucleus
test (MNT). Towards the path to candidate nomination, compound
2 was found to induce micronuclei formation in both the MNT and
HCA in vitro assays in the absence of compound metabolism using
the liver S9 fraction (-S9). However, it was determined to be non-
genotoxic in the Ames test, suggesting that neither the MNT or
HCA result was directly due to DNA mutation. In this Letter we de-
scribe our efforts to eliminate the risk for carcinogenicity while
simultaneously improving selectivity for PI3Kd through structure
based design.
As a means to understanding the origins of the observed in vitro
genotoxicity of compound 2, we tested a series of three additional
compounds that contain a single structural modiﬁcation. Indazole
4 and a benzimidazole 5 with the thienopyrimidine core were not
genotoxic in vitro. These structure–activity relationships suggested
that the purine core may be associated with the observed genotox-
icity. Interestingly however, while compound 2 was genotoxic in
both the MNT and HCA assays, purine 6 did not induce chromo-
somal abnormalities under these conditions. The genotoxicity
SAR for this small subset of molecules suggested that the combina-
tion of a purine core with a benzimidazole moiety was responsible
for the genotoxicity observed in the MNT and HCA assays. Geno-
toxicity testing in the presence of metabolic activation (liver S9
fractions) yielded negative results in both the MNT and HCA assays
for all compounds tested, indicating that the parent molecule was
responsible for eliciting a genotoxic signal.
We primarily utilized two complementary in vitro assays in
mammalian cell lines for the identiﬁcation of chromosomal dam-
aging agents: (1) the in vitro micronucleus test (MNT), capable of
identifying aneugens and clastogens, and (2) the human chromo-
somal aberration test (HCA), speciﬁc for the identiﬁcation of clast-
ogens.16–18 Aneugens differ from clastogens, in that they lead to
chromosomal gain or loss through interactions with the spindle
apparatus, whereas clastogens generally cause chromosomal
breaks through possible interactions with DNA. Material require-
ments for both the MNT and HCA assays are generally high, typi-
cally requiring several hundred milligrams of highly pure
material. However, the in vitro MNT assay is amenable to automa-
tion by the use of ﬂuorescent microscopy paired with high
throughput image-analysis for the detection of micronuclei in
CHO-K1 cells.19 Lower material requirements and rapid assess-
ment from the high-content MNT (HC-MNT) assay allowed us to
quickly determine both genotoxicity risk and subsequently assess
structure–activity relationships to further enhance design of new
analogs. When compared with manual scoring, the automatedscoring method was found to be predictive 100% of the time for po-
sitive ﬁndings and 76% of the time for negative ﬁndings in a test set
of drugs.19 Moreover, a high level of concordance has been demon-
strated between the manual in vitro MNT assay and the in vitro
HCA assay. Our screening cascade initially included assessment
in both the in vitro MNT and HCA assays. In addition to genetic
tests, biochemical potencies for PI3K isoforms (a, b, d, c) were
determined using a competitive ﬂuorescence polarization assay
measuring PI3K mediated formation of PIP3.12 Cellular potencies
were determined in human whole blood by monitoring B cell
expression of CD69, a cell surface marker for lymphocyte activa-
tion.20,21 Compounds 2–6, 23–28, 34, and 37 were synthesized
according to published procedures or in a manner similar.12–14,22
nitrogen linked analogs 32, 33, and 36 were synthesized according
to Scheme 1. Amide analogs 29 and 30were synthesized according
to Scheme 2. Carbon linked analogs 35 and 38 were synthesized
according to Scheme 3, via a Horner–Wadsworth–Emmons oleﬁn-
ation followed by hydrogenation.
As a result of the initial SAR matrix, we set out to further ex-
plore the two speciﬁc structural regions of compound 2 Figure 2,
(a) methylene region and (b) 2-benzimidazole region. Our aim
was to disrupt the structural features responsible for in vitro geno-
toxicity by restricting conformational preferences and decreasing
structural planarity. The two regions outlined above had yet to
be fully explored and offered an opportunity to modulate interac-
tions with the selectivity and afﬁnity regions of the ATP-binding
pocket.11,12
Initial genotoxicity determination for several compounds with
different substituents in the 2-position of the benzimidazole
quickly led us to identify several compounds testing negative in
the HC-MNT assay. Interestingly, there tended to be a correlation
between molecular volume of the 2-benzimidazole group and
micronuclei formation in the MNT assay (i.e., compounds 2, 23–
27, Table 2). Surprisingly however, results from the HCA assay
were not in concordance with the MNT results (compounds 25–
27). We attributed this lack of correlation to the difference in the
cell type used in the MNT (CHO-K1) and HCA (human lympho-
cytes) assays. Compound 26 has acceptable kinetic solubility
(32 lM) and was found to be potent (PI3 Kd Kiapp = 2.0 nM) and
moderately selective for PI3Kd (PI3Ka/d = 59) with overall excel-
lent kinase selectivity in invitrogen’s 276 kinase panel at 10 lM
(B-Raf-V599E was inhibited at 53%, MELK at 63% and PI3KC2b at
72%).
The genotoxicity data obtained for compounds 2, 4, 5, 6 (Table 1)
demonstrated that the clastogenicity observed in the HCA assay
was not due to inhibition of the PI3K enzymes. It was also clear
from these experiments that subtle modiﬁcation of the properties
of the central bicycle and the position of the piperidine group could
change the genotoxicity proﬁle of our compounds. Further optimi-
zation therefore focused on exploration of the methylene linker of
the lead compounds. We reasoned that modiﬁcation of this group
would allow us to further optimize the selectivity proﬁle of our
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Figure 2. Structural features identiﬁed as being related to genotoxicity ﬁndings.
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Scheme 3. Reagents and conditions: (a) NaBH4, MeOH, 0 C, 1 h, 92%; (b) PBr3, DCE, THF, 0 C, 1 h, 77%; (c) P(OCH3)3, 80 C, 2 h, 86%; (d) tert-butyl 3-oxoazetidine-1-
carboxylate, LDA, THF, 78 C to rt, 93%; (e) 2-ethylbenzimidazole, Cs2CO3, XPhos, Pd2(dba)3, DMF, 130 C, 35 min, 59%; (f) 10% Pd/C, EtOH, AcOH, H2 atm, rt, 24 h, 86%; (g)
TFA, rt, 1 h, 36%; (h) dihydro-2H-thiopyran-4(3H)-one 1,1-dioxide, NaBH(OAc)3 DCM, rt, 15 min, 26%; (i) iPrCOCl, Et3N, DCM, rt, 2 h, 86%.
N
NN
N N
N
O
Me
I
N
N
NN
N N
N
O
Me
N
NN
R2
R1
8: R1 = H, R2 = Boc
9: R1 = Me, R2 = Boc
10: R1 = Me, R2 = H
11: R1 = H, R2 = H
33, 36
32
a
e
b f
c g
7
d
S
O
O O
R2 =
32, 33 36
Scheme 1. Reagents and conditions: (a) tert-butyl azetidin-3-ylcarbamate, Cs2CO3, XPhos, Pd2(dba)3, THF, 100 C, 8 h, 74%; (b) TFA, DCM, 0 C, 1 h, 95%; (c) dihydro-2H-
thiopyran-4(3H)-one 1,1-dioxide, NaBH(OAc)3 DCE, rt, 20 h, 37%; (d) isobutyryl chloride, Et3N, DCM, rt, 2 h, 95%; (e) NaH, MeI, THF, rt, 3 h, 98%; (f) TFA, DCM, 0 C, 1 h, 92%; (g)
dihydro-2H-thiopyran-4(3H)-one 1,1-dioxide, NaBH(OAc)3) DCE, MeOH, rt, 20 h, 84%.
a, b c
12: X = N, Y = NMe
13: X = S, Y = CMe
14: X = N, Y = NMe
15: X = S, Y = CMe
N
NX
Y N
N
O
O
HO
NN
NX
Y Cl
N
O
O
N
N
N
O
N
N
N
N
H2N
O
29: X = N, Y = NMe
30: X = S, Y = CMe
O X
Y
Scheme 2. Reagents and conditions: (a) 2-ethylbenzimidazole, Cs2CO3, XPhos, Pd2(dba)3, DMF, 145 C, 30 min, microwave, 43%; (b) AgNO2, NaOH, EtOH, water, rt, 30 min,
19%; (c) 2-methyl-2-(piperazin-1-yl)propanamide, HBTU, DIEA, DMF, rt, 38–66%.
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tral bicycle and the relative conformational disposition of the
piperidine and bicyclic units.
We ﬁrst sought to understand the conformational preferences
required for selectivity to inform target selection. Previously re-
ported structural studies suggested that benzimidazole inhibitors
engaged in hydrophobic contacts with Trp760 had improved selec-
tivity for inhibition of PI3Kd relative to PI3Ka10,11 docking and
crystallographic studies suggested two major conformations of
inhibitor 25 that may affect interactions with Trp760 and ulti-
mately impact PI3Kd/PI3Ka selectivity (Fig. 3). In the ﬁrst confor-
mation (Fig. 3A), the dihedral angle between the amine group
Table 1
N
N
N
O
R1
SN
HO
N
N
N
O
R1
N
N
N
Me
HO
Compound R1 P13k-dKiapp Compound P13k-dKiapp
MNT HCA MNT HCA
4
NH
N 1.1 nM
6
2.3 nM
Negative Negative Negative Negative
— — — —
5 N
N
5.5 nM
2
2.0 nM
Negative Negative Positive Positive
— — + +
Table 2
Genotoxicity data for 2-benzimidazole analogs
N
N
N
O
N
N
N
N
Me
HO
NR
Compound R Volumea MNT HCA
23 Me 0 + +
24 NHMe 13 + nd
2 Et 18 + +
25 NMe2 30  +
26 iPr 34  +
27 cPr 28  +
a Van der Waals volume was computed using MOE (Chemical Computing
Group,version 2012.10).
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allows for the inhibitors to make a hydrophobic contact with
Trp760 and, based on the differential PI3Ka/PI3Kd interactions
accessible in this conformation could be considered to be inher-
ently more selective for PI3Kd. The second relevant conformation
(Fig. 3B) features a dihedral angle between the amine group and
the purine N(7) of 150 degrees. This torsional angle is observed
for the non-PI3K-selective inhibitor 3 (GDC-0941) in co-crystal
structures with PI3Ka and PI3Kc10 Close inspection of 25 bound
to PI3Kdin the ‘selective’ conformation revealed that there may
be electronic repulsion between the weakly basic benzylic piperi-
dine nitrogen atom of 25 and the N(7) of the purine ring.23 Small
molecule crystal structures of similar ring systems adopt a confor-
mation that more closely resembles the less selective conformation
(dihedral angle = 115).24 We proposed that electron–electron
repulsion between the benzylic nitrogen and purine N(7) favors
the less selective extended conformation (Fig. 3B). Following this
hypothesis, we designed analogs that should preferentially adopt
a selective conformation (dihedral angle <30). This strategy en-
abled us to simultaneously explore the effect of substitution and
conformational restriction on genotoxicity for this series of
inhibitors.Substitution of the benzylamine group in 28 for an amide link-
age (28 and 29, Table 3) should address several of the consider-
ations described above. In this case, electronic repulsion between
the introduced amide carbonyl group and N(7) of the purine core
should strongly favor a more selective conformation in which the
amide carbonyl is anti-periplanar to N(7), positioning the pipera-
zine group near the targeted Trp residue. Preparation of key ami-
do-purine inhibitor 29 revealed that this compound did have
signiﬁcantly improved selectivity relative to methylene-linked
inhibitor 28 (Table 3). This improvement resulted from a small
but distinct improvement in potency against PI3Kd as well as a sig-
niﬁcant reduction in potency against PI3Kd interestingly, replace-
ment of the methylene unit with a carbonyl group had reduced
PI3Ka/PI3Kd selectivity in the context of a thiaenopyrimidine core
(compound 30, Table 3). In the thiaphenopyrimidine case, the well-
known attractive interaction between amide carbonyl groups and
the r* orbital of sulfur atoms should favor the less selective con-
formation.25 Gratifyingly, amide 29 tested negative in the in vitro
HCA assay, justifying further exploration along these lines.
We therefore targeted an additional series of compounds
replacing the methylene moiety with heteroatoms to explore their
effect on selectivity and genotoxicity. Although these inhibitors are
less likely to be more conformationally restricted than inhibitor 29
(amide), a series of carbon (black), oxygen (green) and nitrogen
(blue, red) linked purine model systems were evaluated computa-
tionally using simipliﬁed fragments of the targeted molecules
(Fig. 4). Ab initio calculations indicated that ligand ground-state
energies would slightly favor a selective conformation (30) over
a less selective extended conformation (150). In particular,
amide (orange) and oxygen linked (green) model systems were
predicted to greatly disfavor the less selective extended conforma-
tion. Several analogs were selected for synthesis, and further eval-
uated (Table 4).
Comparison of compounds 2 and 31 once again establishes the
selectivity improvements from methylene to amide in the context
of the purine core, as described above. As predicted from our com-
putational studies (Fig. 4, red), –NMe– linked compounds yielded
inferior selectivity to the other heteroatom linkages, possibly be-
cause the undesired conformational bias imposed by the N(CH3)
linkage (i.e., compound 32). While –NH– linked compounds pro-
vided high selectivity, permeability appeared to be adversely af-
fected, likely due to the addition of a single hydrogen bond
donor (i.e. compounds 33 and 36). These compounds also had rel-
atively poor potency in our human whole blood cellular assay (i.e.,
compound 33). Oxygen (–O–) and carbon (–C–) linked compounds
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Figure 3. Comparison of the modeled conformations of compound 25 bound to a homology model of PI3Kd (gray) and PI3Ka (cyan). (A) Selective conformation: In PI3Kdwith
Thr750, hydrophobic Trp760 is solvent-exposed and allows favorable packing interaction with the bulky piperidinyl substitution of the compound.The unsigned dihedral
angle is 26 which is close to the lowest-energy conformation of the free ligand. (B) Unselective conformation: in PI3Ka, Trp780 interacts with Arg770, which disfavors the
previous ligand binding conformation. Now the piperidinyl substitution rotates to an unsigned dihedral of 120, which is a slightly higher energy conformation of the free
ligand.
Table 3
SAR of amide linker
N
N
N
O
N
N
N
N
H2N
O
Compound R Kiapp (nM) Fold
PI3K-d PI3K-a a/d
28
N
N
Me
H
H 7
1.8 110 63
29
N
N
Me
O 7
0.8 236 293
30
S
Me
O
12.7 157 12
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conformations with a minimal dihedral angle (Fig. 4, green andblack), possessed excellent potency (PI3Kd Kiapp <1 nM) and selec-
tivity (PI3Ka/PI3Kd 145–256) but differed greatly in their pharma-
cokinetic properties. In rat in vivo studies, the carbon linked series
generally was cleared at rates above liver blood ﬂow (i.e. 35,
CL = 63 mL/min/kg) and had high predicted human hepatic clear-
ance (16 mL/min/kg) based on liver microsomal incubations. Oxy-
gen-linked compounds, such as 34 showed improved in vitro and
in vivo pharmacokinetic behavior. This series of compounds also
exhibited high permeability in vitro and had excellent potency in
our human whole blood (HWB) assay (compound 34, CD69 HWB
IC50 = 4.38 nM).
Advanced proﬁling of 34 enabled us to further differentiate our
selective PI3Kd inhibitors prepared during the course of our opti-
mization program. Compound 34 exhibited excellent PI3K isoform
selectivity and broad kinase selectivity through invitrogen’s 239 ki-
nase panel at 1 lM (only B-Raf was inhibited at 61% and PI4Kb at
71%). This compound had low predicted hepatic clearance in hu-
man (1.7 mL/min/kg), dog and rat, based on hepatocyte incuba-
tions (Table 5). Compound 34 was also evaluated in intravenous
and oral in vivo studies. Clearance in the dog was low and consis-
tent with the predicted hepatic clearance, while in the rat plasma
clearance was moderate (between 30% and 70% of hepatic blood
ﬂow). Compound 34’s low intrinsic clearance and moderate per-
meability (MDCK Papp A to B 8.23  106) led to igh oral absorption
(F% = 82–100%) and acceptable half-lifes (T1/2 = 2.59–11.6 h). With
increased dose in dog, plasma exposures (Cmax and AUC) also in-
creased in a linear manner. The overall pharmacokinetic proﬁle is
predicted to be capable of supporting QD dosing, while maintain-
ing HWB IC90 target inhibition over 24 h in man.
Oxygen linked compound 34 tested negative for genotoxicity in
the in vitro HCA assay (Table 6). Using DMSO and mitamycin C
Table 4
General SAR of amide, carbon, oxygen and nitrogen linked analogs related to potency and selectivity
N
N
N
O
N
NR2
N
N
R1
Compound R1 X R2 Kiapp (nM) Fold CD69
HWB
IC50(nM)
PI3K-d a/d b/d c/d
2 X
N
HO
CH2 Et 2.0 67 131 110 21.3
31 CO Et 3.1 136 485 72 52.8
32
N
S
O
O
X NMe Et 0.59 90 135 119 1.79
33 NH Et 0.90 301 216 153 80.2
34 O iPr 0.47 256 420 219 4.38
35 CH2 Et 0.23 254 261 350 4.02
36
N
O
X NH Et 0.88 130 147 90.8 nd
37 O Et 0.58 145 160 191 11.9
38 CH2 Et 0.36 153 260 128 9.96
Figure 4. Torsional energy proﬁles of ﬁve types of linkers calculated by QM. The corresponding dihedral angles are in bold red. Red arrow marks the conformation that is
predicted to give optimal isoform selectivity (25).
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mosome aberrations were performed after achieving maximum
soluble concentrations at 50% cytotoxicity (mitotic index = 5).
Ultimately, the occurrence of chromosomal breaks was greatly re-
duced from 44% for 26 to an acceptable level of 2% for 34 at equal
or higher concentrations, leading to a negative HCA result. We
hypothesize that our efforts to improve selectivity by reducing
the accessible conformations not only favored potency andselectivity for our target, but also favored the negative result ob-
served in the in vitro HCA assay.
In summary, we have discovered a highly potent and selective
class of oxygen linked PI3Kd inhibitors. Our starting point 2
possessed moderate selectivity and tested positive for genotoxicity
in both the HC-MNT and HCA assay. Compounds testing negative
in the HC-MNT assay were successfully identiﬁed through
modiﬁcations of the molecular volume of the 2-benzimidazole
Table 5
Pharmacokinetic parameters for compound GNE-293 (34)
N
N
N
O
N
N
N
N
O
N
S
O O
GNE-293 (34)
Species In vitro hepatocyte
CLhep (mL/min/kg)
PPB (%) IV (1 mg/kg) PO
In vivo CL (mL/min/kg) Vdss (L/kg) T1/2 (h) Dose (mg/kg) %F Cmax(lM) AUC (lM h)
Rat 1.4 81.7 19.4 3.6 2.59 5 96.2 1.18 7.23
Dog 6.2 80.0 2.3 2.2 11.6 2 82.6 1.74 21.1
10 100 8.81 128
Table 6
Comparison of in vitro HCA data for compounds 26 and GNE-293 (34)
Compound Max. concn
(l/mL)
Mitotic
index
Chromosomal
breaks%
Judgement
(+/)
DMSO(vehicle) 10 11.1 0 Negative 
MMC(control) 0.300 na 32 Positive +
26 Positive +
GNE-293(34) 62.5 6.8 2 Negative 
B. S. Saﬁna et al. / Bioorg. Med. Chem. Lett. 23 (2013) 4953–4959 4959substituent. However, these analogs continued to test positive in
the HCA assay. Shifting our focus to the methylene linker region,
we explored a variety of conformationally restrictive linker
replacements. Groups that restrict torsional angles (<30) to favor
ligand interactions with PI3Kd’s Trp760 provided a variety of ana-
logs with increased PI3Kd potency and selectivity. Lead compound
GNE-293 (34) tested negative in the HCA assay and possessed
favorable pharmacokinetic properties.
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